NIKKEI 225
38,638.67 +5.65 (+0.01%) HANG SENG
18,011.22 -324.10 (-1.77%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,376.60 +7.60 (+0.32%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,966.51 -626.05 (-1.21%)
REGN Nov 2024 975.000 call
- Zacks
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
- GlobeNewswire
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
- Simply Wall St.
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
